The next wave of amyloid-targeting projects approachesGreat Article;
Other oliogomer-targeting projects are at the preclinical stage, and Acumen lists the likes of Alzinova, Promis Neurosciences, Kalgene Pharmaceuticals and Wren Therapeutics among its potential rivals. The last two groups are privately held – maybe a resurgence of interest in amyloid-beta could prompt them to follow Acumen onto the public markets.
https://www.evaluate.com/vantage/articles/analysis/spotlight/next-wave-amyloid-targeting-projects-approaches